GlassScriptPhysician profile
Bobby Allen Brite
NPI 1598262040
$2,310.30
in general payments reported to CMS, 2019-2025
24 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,188 · 2022: $174 · 2023: $369 · 2024: $126 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $948.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $583.41 | 2021-2025 | Jardiance, Mounjaro, Emgality |
| Novo Nordisk INC | $403.62 | 2021-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $159.66 | 2021-2025 | |
| Abbvie INC. | $150.75 | 2021-2023 | |
| Glaxosmithkline, LLC. | $134.61 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.21 | 2021-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $119.51 | 2021 | |
| Corcept Therapeutics | $115.31 | 2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $58.14 | 2021-2025 | Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $55.49 | 2021 | |
| Genentech USA, INC. | $53.94 | 2021-2022 | |
| Amgen INC. | $49.46 | 2021-2025 | Repatha, Otezla |
| Exact Sciences Corporation | $42.53 | 2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $34.50 | 2021 | |
| Supernus Pharmaceuticals, INC. | $34.13 | 2021 | Xyosted |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $30.92 | 2021 | |
| Esperion Therapeutics, INC. | $27.08 | 2021 | |
| Eisai INC. | $26.08 | 2021 | |
| Shield Therapeutics INC | $22.01 | 2025 | |
| Janssen Pharmaceuticals, INC | $19.98 | 2024 | Spravato |
| Halozyme INC | $17.86 | 2023 | |
| Antares Pharma, INC. | $17.06 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.52 | 2021 | |
| Currax Pharmaceuticals LLC | $12.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bobby Brite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.